For its third fiscal quarter (ending September 30), Core Laboratories NV (NYSE: CLB) has reported E.P.S. of $0.25 compared to $0.20 a year ago. E.P.S. were $0.57 for the latest four quarters through September 30 versus $0.88 for the same period a year ago.
Recent Price Action
Core Laboratories NV (NYSE: CLB) stock declined slightly by -1.0% on 10/23/24. The stock closed at $17.08. Moreover, this decline was accompanied by unusually high trading volume at 171% of normal. The stock has been exceptionally strong relative to the market over the last nine months but has declined -5.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, CLB is expected to continue to be a major Value Builder.
Core Laboratories has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Core Laboratories has a poor Appreciation Score of 16 but a good Power Rating of 80, and the Low Neutral Value Trend Rating results.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment